Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Paul Senior who wrote (16341)	2/3/2003 2:27:37 AM
From: RRICH4	Respond to of 78523

From RealMoney on KG, King Pharma: 1/31/03 This morning, B of A released a report titled "Sell-of on Elan primary care purchase overdone" I am sure others will follow. The company has raised 2003 guidance, as it said it would on the PM conf call yesterday. It is now expecting 2003 full year of $1.60 to $1.78. Previous guidance was $1.54 to $1.66. However, for 1q03 the company is estimating 33 cents to 37 cents, at or below the analysts concensus of 37 cents. Even at the most conservative level of earnings of $1.54 this company is too cheap to pass up.